Semaglutide is a Glucagon Like Peptide 1 (GLP-1) receptor agonist recently approved in Israel
to improve glycemic control in patients with type 2 diabetes mellitus. Semaglutide is
currently administered as a weekly subcutaneous injection.Treatment with semaglutide is
associated with the occurrence of gastrointestinal adverse events (GI-AEs) commonly observed
during GLP-1 receptor agonist treatment. The most common adverse reactions, reported in ≥5%
of patients treated with semaglutide are nausea, vomiting, diarrhea, abdominal pain and
constipation.
In this trial we plan to explore the effect of a slower titration regimen of semaglutide vs.
the current label-recommended dose escalation regimen on the occurrence of GI-AEs.